|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-10-1
|
|
pubmed:abstractText |
Fulvestrant ('Faslodex') is an oestrogen receptor (ER) antagonist with no agonist effects. The drug was administered to heavily pre-treated patients with advanced breast cancer (ABC). Patients received Fulvestrant after disease progression (PD) on a previous endocrine treatment or as maintenance treatment after chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0167-6806
|
|
pubmed:author |
pubmed-author:AdamoliLauraL,
pubmed-author:AscioneGildaG,
pubmed-author:CataniaChiaraC,
pubmed-author:De PasTommasoT,
pubmed-author:FranceschelliLuciaL,
pubmed-author:GoldhirschAronA,
pubmed-author:MagniElenaE,
pubmed-author:MediciMartaM,
pubmed-author:NolèFrancoF,
pubmed-author:SannaGiuseppinaG,
pubmed-author:TorrisiRosalbaR,
pubmed-author:VerriElenaE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
106
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
97-103
|
|
pubmed:meshHeading |
pubmed-meshheading:17260095-Adult,
pubmed-meshheading:17260095-Aged,
pubmed-meshheading:17260095-Aged, 80 and over,
pubmed-meshheading:17260095-Antineoplastic Agents, Hormonal,
pubmed-meshheading:17260095-Breast Neoplasms,
pubmed-meshheading:17260095-Disease Progression,
pubmed-meshheading:17260095-Drug Resistance, Neoplasm,
pubmed-meshheading:17260095-Empathy,
pubmed-meshheading:17260095-Estradiol,
pubmed-meshheading:17260095-Estrogen Antagonists,
pubmed-meshheading:17260095-Female,
pubmed-meshheading:17260095-Humans,
pubmed-meshheading:17260095-Injections, Intramuscular,
pubmed-meshheading:17260095-Middle Aged,
pubmed-meshheading:17260095-Program Evaluation,
pubmed-meshheading:17260095-Prospective Studies,
pubmed-meshheading:17260095-Receptors, Estrogen,
pubmed-meshheading:17260095-Receptors, Progesterone,
pubmed-meshheading:17260095-Time Factors,
pubmed-meshheading:17260095-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
|
|
pubmed:affiliation |
Unit for Medical Care, Division of Medical Oncology, European Institute of Oncology, 20141, Milan, Italy. chiara.catania@ieo.it
|
|
pubmed:publicationType |
Journal Article
|
